What happens when the architect behind the Transformer turns his focus to RNA and molecular design? Jakob Uszkoreit, Co-Founder of Inceptive and co-author of Attention is All You Need, joins John Cumbers, founder and CEO of SynBioBeta, for a conversation at the intersection of AI and biology. As synthetic biology enters the age of hyperscale—powered by generative models, molecular learning, and programmable therapeutics—Jakob shares his vision for reimagining intelligence not just in machines, but in the molecules that power life. Don’t miss this rare dialogue on the future of biodesign, computation, and the growing interface between synthetic biology and deep learning.

P&G is a leading consumer products company led by consumer insights- they can tell you that today’s consumers want clean, healthy products in their homes to provide for their families' personal care needs. To meet these expectations, innovators are integrating new approaches to transform their supply chains, minimize waste streams, and drive environmentally sound solutions for a more sustainable planet. Join two senior leaders for a closer look at how synbio can positively impact consumer products and what specific challenges–both technical and societal–we need to solve to get there. Hear how corporate leaders evaluate new innovations and where they see unmet needs in the market. This session will highlight how corporates and startups can work together to achieve the functional and sustainable performance consumers demand.

In this conversation, we explore the dynamic interplay between public funding and private investment in shaping the next wave of biotechnology breakthroughs and safeguarding regional technology sovereignty. We’ll examine how government agencies fund high-risk, high-reward early-stage research, why America and China have staked their claims in biotechnology leadership, and what Europe must do to forge its own independent capabilities. The discussion will also highlight the critical role of the private sector—from strategic venture investments in sequencing and diagnostics to innovative startup ventures—and the policy frameworks necessary to sustain a vibrant, self-reliant bioinnovation ecosystem.

How does a nation turn bio-revolution headlines into hospital-ready cures? This conversation surveys the full innovation stack—from lab-bench breakthroughs in gene and cell therapies to the gritty realities of bioprocess scale-up, supply-chain resilience, and workforce training. We’ll unpack the manufacturing leaps required to mass-produce living tissues, explore emerging automation that slashes cost and variability, and ask what policies, public-private partnerships, and investment models can keep America at the cutting edge of regenerative medicine. Expect a candid look at the roadblocks ahead—quality-control analytics, raw-material bottlenecks, reimbursement hurdles—and the bold engineering solutions poised to overcome them.

This discussion brings together leaders from global consumer goods and materials companies to examine how engineered proteins can reshape supply chains, improve product performance, and reduce environmental impact. Speakers will share perspectives on building effective industry partnerships, balancing cost efficiency with quality, and navigating regulatory landscapes. The panel aims to understand better the collaborative pathways that turn cutting-edge protein design into widely adopted commercial solutions.